JP2025509285A - ｈＭＰＶ抗体およびそれらの使用 - Google Patents

ｈＭＰＶ抗体およびそれらの使用 Download PDF

Info

Publication number
JP2025509285A
JP2025509285A JP2024553392A JP2024553392A JP2025509285A JP 2025509285 A JP2025509285 A JP 2025509285A JP 2024553392 A JP2024553392 A JP 2024553392A JP 2024553392 A JP2024553392 A JP 2024553392A JP 2025509285 A JP2025509285 A JP 2025509285A
Authority
JP
Japan
Prior art keywords
seq
nos
hmpv
antibody
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024553392A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025509285A5 (https=
Inventor
ジャロッド ムーサ，
ジアチェン ファン，
アヴィク バネルジー，
Original Assignee
ユニバーシティ・オブ・ジョージア・リサーチ・ファウンデイション・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニバーシティ・オブ・ジョージア・リサーチ・ファウンデイション・インコーポレイテッド filed Critical ユニバーシティ・オブ・ジョージア・リサーチ・ファウンデイション・インコーポレイテッド
Publication of JP2025509285A publication Critical patent/JP2025509285A/ja
Publication of JP2025509285A5 publication Critical patent/JP2025509285A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2024553392A 2022-03-07 2023-03-06 ｈＭＰＶ抗体およびそれらの使用 Pending JP2025509285A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263317384P 2022-03-07 2022-03-07
US63/317,384 2022-03-07
PCT/US2023/063801 WO2023172881A1 (en) 2022-03-07 2023-03-06 Hmpv antibodies and their use

Publications (2)

Publication Number Publication Date
JP2025509285A true JP2025509285A (ja) 2025-04-11
JP2025509285A5 JP2025509285A5 (https=) 2026-02-13

Family

ID=87935885

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024553392A Pending JP2025509285A (ja) 2022-03-07 2023-03-06 ｈＭＰＶ抗体およびそれらの使用

Country Status (7)

Country Link
US (1) US20250188153A1 (https=)
EP (1) EP4490180A1 (https=)
JP (1) JP2025509285A (https=)
CN (1) CN119213024A (https=)
AU (1) AU2023232815A1 (https=)
CA (1) CA3254336A1 (https=)
WO (1) WO2023172881A1 (https=)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020236974A1 (en) * 2019-05-21 2020-11-26 University Of Georgia Research Foundation, Inc. Antibodies that bind human metapneumovirus fusion protein and their use

Also Published As

Publication number Publication date
EP4490180A1 (en) 2025-01-15
WO2023172881A1 (en) 2023-09-14
CA3254336A1 (en) 2023-09-14
CN119213024A (zh) 2024-12-27
US20250188153A1 (en) 2025-06-12
AU2023232815A1 (en) 2024-09-26

Similar Documents

Publication Publication Date Title
US20250145690A1 (en) Human monoclonal antibodies that broadly target coronaviruses
CA2908921C (en) Human antibodies binding to rsv g protein
JP2024506315A (ja) コロナウイルスのスパイクタンパク質を標的とする抗体
US12559544B2 (en) Antibodies that bind human metapneumovirus fusion protein and their use
JP2025507595A (ja) コロナウイルスＳＡＲＳ－ＣｏＶ－２のスパイクタンパク質に結合することができる抗体
US12612449B2 (en) HIV-1 antibodies
WO2022132904A1 (en) Human monoclonal antibodies targeting sars-cov-2
WO2022065445A1 (ja) ＳＡＲＳ－ＣｏＶ－２中和抗体又はその断片
US20260062464A1 (en) Monoclonal antibodies that bind to the underside of influenza viral neuraminidase
EP4638491A1 (en) Monoclonal antibodies for treating sars-cov-2 infection
US20250188153A1 (en) Hmpv antibodies and their use
EP4291306A1 (en) Human monoclonal antibodies against pneumococcal antigens
WO2024054822A1 (en) Engineered sars-cov-2 antibodies with increased neutralization breadth
WO2025137284A2 (en) Broadly neutralizing antibodies against sars-cov-2 and sars-cov variants
WO2025117384A1 (en) Broadly neutralizing influenza hemagglutinin stem-directed antibodies
JP2024535249A (ja) 合成ヒト化ラマナノボディライブラリーおよびｓａｒｓ－ｃｏｖ－２中和抗体を同定するためのその使用
WO2025024233A1 (en) Bispecific antibodies that broadly target coronaviruses
WO2022133545A1 (en) Sars-cov-2 antibodies

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260204

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260204